



TTK Healthcare
LIMITED

TTKHC:SECL:GJ:178:19

August 09, 2019

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Unaudited Financial Results along with Limited Review Report for the First Quarter
ended 30th June, 2019 (Standalone)**

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the First Quarter ended 30th June, 2019 (Standalone), duly reviewed by the Audit Committee at their meeting held yesterday and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl. : a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

Sl. No.	Particulars	(Rs. in lakhs)			
		For the Quarter ended			For the Year ended
		(30/06/2019)	(31/03/2019)	(30/06/2018)	(31/03/2019)
		Unaudited	Audited	Unaudited	Audited
I.	Revenue from Operations	17,859.06	13,960.79	17,313.10	62,788.36
II.	Other Income	185.70	228.18	183.35	775.35
III.	Total Income (I + II)	18,044.76	14,188.97	17,496.45	63,563.71
IV.	Expenses				
	(a) Cost of materials consumed	2,426.48	2,351.15	2,289.14	10,124.91
	(b) Purchase of Stock-in-trade	5,129.05	3,832.74	4,643.67	16,711.14
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(100.61)	(209.30)	125.76	(576.99)
	(d) Employee benefits expense	3,754.72	3,253.15	3,395.71	13,070.09
	(e) Finance Costs	68.02	68.90	104.93	337.90
	(f) Depreciation and Amortization Expense	354.44	408.49	363.82	1,466.85
	(g) Other Expenses	5,804.10	3,752.31	5,277.93	18,503.86
	Total Expenses (IV)	17,436.20	13,457.44	16,200.96	59,637.76
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	608.56	731.53	1,295.49	3,925.95
VI.	Exceptional Items	-	-	-	-
VII.	Profit / (Loss) before Tax (V - VI)	608.56	731.53	1,295.49	3,925.95
VIII.	Tax Expense:				
	(1) Current Tax	238.00	315.00	490.00	1,495.00
	(2) Deferred Tax	6.63	(78.93)	17.69	(6.42)
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	363.93	495.46	787.80	2,437.37
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-
XI.	Tax Expense of Discontinued Operations	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	363.93	495.46	787.80	2,437.37
XIV.	Other Comprehensive Income:				
	(A) (i) Items that will not be reclassified subsequently to profit or loss	(91.89)	39.18	(58.48)	234.17
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(6.40)	25.75	-	25.75
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]	265.64	560.39	729.32	2,697.29

	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet of previous accounting year (including Revaluation Reserve)	-	-	-	23,729.96

XVI.	Earnings per Equity Share (For Continuing Operations):				
(1)	Basic (in Rs.)	2.58	3.51	5.58	17.25
(2)	Diluted (in Rs.)	2.58	3.51	5.58	17.25
XVII.	Earnings per Equity Share (For Discontinued Operations):				
(1)	Basic (in Rs.)	-	-	-	-
(2)	Diluted (in Rs.)	-	-	-	-
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):				
(1)	Basic (in Rs.)	2.58	3.51	5.58	17.25
(2)	Diluted (in Rs.)	2.58	3.51	5.58	17.25

Notes:

- (1) The above results have been reviewed by the Audit Committee at their meeting held on 8th August, 2019 and approved by the Board of Directors of the Company at their meeting held on 9th August, 2019 at Chennai.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) The Company has implemented Ind AS 116 "Leases", with effect from 1st April, 2019 and the effect of the same is not material.
- (4) The figures for the Quarter ended 31st March, 2019 are the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures upto the end of the Third Quarter of relevant financial year, which was subjected to Limited Review.
- (5) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (6) This Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : August 09, 2019



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER ENDED 30TH JUNE, 2019

Sl. No.	Particulars	(Rs. in lakhs)			
		For the Quarter ended			For the Year ended
		(30/06/2019)	(31/03/2019)	(30/06/2018)	(31/03/2019)
		Unaudited	Audited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)				
(a)	Pharmaceuticals	6,026.58	4,903.54	5,553.63	21,645.89
(b)	Consumer Products	6,127.36	3,891.54	6,259.00	18,999.26
(c)	Medical Devices	1,199.41	1,074.21	1,133.80	4,286.97
(d)	Protective Devices	2,293.95	2,030.39	2,749.95	10,313.83
(e)	Foods	2,180.83	2,034.84	1,595.53	7,470.06
(f)	Others	30.93	26.27	21.19	72.35
	Total	17,859.06	13,960.79	17,313.10	62,788.36
	Less : Inter Segment Revenue	-	-	-	-
	Net Sales / Income from Operations	17,859.06	13,960.79	17,313.10	62,788.36
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]				
(a)	Pharmaceuticals	515.18	531.10	424.02	2,110.62
(b)	Consumer Products	605.46	473.22	1,130.00	3,324.73
(c)	Medical Devices	207.38	237.78	275.01	935.26
(d)	Protective Devices	(163.29)	26.55	(5.17)	(262.84)
(e)	Foods	(254.55)	(240.75)	(177.13)	(847.21)
(f)	Others	15.75	18.93	10.68	44.13
	Total	925.93	1,046.83	1,657.41	5,304.69
	Less : Finance Cost	68.02	68.90	104.93	337.90
	Less : Unallocable Expenses (Net of Unallocable Income)	249.35	246.40	256.99	1,040.84
	Total Profit (+) / Loss (-) before tax	608.56	731.53	1,295.49	3,925.95
		As on	As on	As on	As on
		30/06/2019	31/03/2019	30/06/2018	31/03/2019
3.	Segment Assets				
(a)	Pharmaceuticals	6,575.60	5,627.36	5,050.10	5,627.36
(b)	Consumer Products	4,424.77	3,229.20	3,498.91	3,229.20
(c)	Medical Devices	4,275.66	4,018.25	3,638.30	4,018.25
(d)	Protective Devices	8,368.60	8,009.33	8,961.40	8,009.33
(e)	Foods	9,187.44	8,918.46	9,739.10	8,918.46
(f)	Others	144.30	122.11	90.60	122.11
	Total	32,976.37	29,924.71	30,978.41	29,924.71
	Unallocated	14,782.23	14,250.03	13,491.78	14,250.03
	Total Assets	47,758.60	44,174.74	44,470.19	44,174.74

4.	Segment Liabilities				
(a)	Pharmaceuticals	6,248.87	5,188.06	4,573.01	5,188.06
(b)	Consumer Products	5,639.67	4,771.64	5,263.48	4,771.64
(c)	Medical Devices	971.99	865.09	958.71	865.09
(d)	Protective Devices	1,952.05	1,413.48	2,275.34	1,413.48
(e)	Foods	1,169.33	903.64	761.19	903.64
(f)	Others	144.74	138.01	140.38	138.01
	Total	16,126.65	13,279.92	13,972.11	13,279.92
	Unallocated	4,993.48	4,755.49	4,823.37	4,755.49
	Total Liabilities	21,120.13	18,035.41	18,795.48	18,035.41

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Pharmaceuticals include products for both Human and Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : August 09, 2019

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019**(Rs. in lakhs)**

Sl. No.	Particulars	For the Quarter ended			For the Year ended
		(30/06/2019)	(31/03/2019)	(30/06/2018)	(31/03/2019)
		Unaudited	Audited	Unaudited	Audited
1.	Total income from Operations	17,859.06	13,960.79	17,313.10	62,788.36
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	608.56	731.53	1,295.49	3,925.95
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	608.56	731.53	1,295.49	3,925.95
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	363.93	495.46	787.80	2,437.37
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	265.64	560.39	729.32	2,697.29
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per the Balance Sheet of previous accounting year	-	-	-	23,729.96
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)				
	(a) Basic (in Rs.)	2.58	3.51	5.58	17.25
	(b) Diluted (in Rs.)	2.58	3.51	5.58	17.25

Notes:

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the First Quarter ended 30th June, 2019, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the First Quarter ended 30th June, 2019 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (3) The Company has implemented Ind AS 116 "Leases", with effect from 1st April, 2019 and the effect of the same is not material.
- (4) The figures for the Quarter ended 31st March, 2019 are the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures upto the end of the Third Quarter of relevant financial year, which was subjected to Limited Review.
- (5) These financial results have been reviewed by the Audit Committee at their meeting held on 8th August, 2019 and approved by the Board of Directors of the Company at their meeting held on 9th August, 2019 at Chennai.
- (6) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (7) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED


T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : August 09, 2019

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

Independent Auditor's Review Report on review of Interim financial results

To the Board of Directors of TTK Healthcare Limited

We have reviewed the Unaudited financial results of TTK Healthcare Limited ("the Company") for the quarter ended 30th June 2019 ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing obligations) which has been initiated by us for identification purposes.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matter

Attention is drawn to the fact that the figures for the quarter ended 31st March 2019 as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subjected to a limited review.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S/S200018

S. Rajeshwari

Partner

Membership No. 024105



Place: Chennai

Date: 09-08-2019